$VCNX News

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Vaccinex To Report New Clinical Results Of Neoadjuvant Treatment With Pepinemab To Enhance Immunotherapy In Patients With Head And Neck Cancer At ASCO Annual Meeting

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex To Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at AACR in Chicago

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Vaccinex shares are trading lower after the company announced it received a delisting notification from Nasdaq.

Vaccinex Announces Nasdaq Delisting Notification

Vaccinex Has Been Granted Australian Patent Number 2018237549 Titled "Treatment Of Cancer With A Semaphorin-4d Antibody In Combination With An Epigenetic Modulating Agent"

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Q3 EPS $(2.83) vs $(15.25) YoY, Revenue $52K vs $20K YoY; Cash, Cash Equivalents And Marketable Securities As Of Sept. 30 Were $2.9M

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Vaccinex Announces Signing Of Proprietary Project Agreements With Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ThirdArc And Incyte To Employ Vaccinex's ActivMAb Technology

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Vaccinex Reports Improved Immunity Correlating With Clinical Benefit Of Pepinemab Combination Treatment At Society For Immunotherapy Of Cancer's Annual Meeting

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain